Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBITDA (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBITDA for 11 consecutive years, with -$95.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 27.24% to -$95.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$412.3 million, a 20.46% increase, with the full-year FY2025 number at -$412.3 million, up 20.46% from a year prior.
  • EBITDA was -$95.7 million for Q4 2025 at Intellia Therapeutics, up from -$101.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$46.2 million in Q1 2021 to a low of -$152.3 million in Q1 2022.
  • A 5-year average of -$107.8 million and a median of -$109.9 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 229.53% in 2022, then skyrocketed 35.43% in 2023.
  • Intellia Therapeutics' EBITDA stood at -$83.7 million in 2021, then crashed by 33.22% to -$111.5 million in 2022, then decreased by 17.35% to -$130.8 million in 2023, then dropped by 0.57% to -$131.6 million in 2024, then grew by 27.24% to -$95.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's EBITDA are -$95.7 million (Q4 2025), -$101.0 million (Q3 2025), and -$101.7 million (Q2 2025).